Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.

The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.

Inclusion Criteria:

• Healthy Caucasians, males or females aged ≥20 and ≤ 45 years or between 65 80 years. Female subjects must be surgically sterile or post-menopausal for at least 12 months prior to the enrolment visit.
• Body Mass Index (BMI) of ≥18 to ≤ 30 kg/m2 and weight of ≥50 to ≤100 kg
• Clinically normal physical findings including heart rate > 45 bpm and laboratory values and normal resting ECG

Exclusion Criteria:

• History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study.
• History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity.
• Subjects with a high decrease in blood pressure within 5 minutes when going from a supine to standing position.